Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 14;5(5):CD013600.
doi: 10.1002/14651858.CD013600.

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review

Sarah J Valk  1   2 , Vanessa Piechotta  3 , Khai Li Chai  4 , Carolyn Doree  5 , Ina Monsef  3 , Erica M Wood  4 , Abigail Lamikanra  6 , Catherine Kimber  5 , Zoe McQuilten  4 , Cynthia So-Osman  7   8 , Lise J Estcourt  9 , Nicole Skoetz  10
Affiliations

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review

Sarah J Valk et al. Cochrane Database Syst Rev. .

Update in

Abstract

Background: Convalescent plasma and hyperimmune immunoglobulin may reduce mortality in patients with respiratory virus diseases, and are currently being investigated in trials as a potential therapy for coronavirus disease 2019 (COVID-19). A thorough understanding of the current body of evidence regarding the benefits and risks is required. OBJECTIVES: To assess whether convalescent plasma or hyperimmune immunoglobulin transfusion is effective and safe in the treatment of people with COVID-19.

Search methods: The protocol was pre-published with the Center for Open Science and can be accessed here: osf.io/dwf53 We searched the World Health Organization (WHO) COVID-19 Global Research Database, MEDLINE, Embase, Cochrane COVID-19 Study Register, Centers for Disease Control and Prevention COVID-19 Research Article Database and trials registries to identify ongoing studies and results of completed studies on 23 April 2020 for case-series, cohort, prospectively planned, and randomised controlled trials (RCTs).

Selection criteria: We followed standard Cochrane methodology and performed all steps regarding study selection in duplicate by two independent review authors (in contrast to the recommendations of the Cochrane Rapid Reviews Methods Group). We included studies evaluating convalescent plasma or hyperimmune immunoglobulin for people with COVID-19, irrespective of disease severity, age, gender or ethnicity. We excluded studies including populations with other coronavirus diseases (severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS)) and studies evaluating standard immunoglobulins.

Data collection and analysis: We followed recommendations of the Cochrane Rapid Reviews Methods Group regarding data extraction and assessment. To assess bias in included studies, we used the assessment criteria tool for observational studies, provided by Cochrane Childhood Cancer. We rated the certainty of evidence using the GRADE approach for the following outcomes: all-cause mortality at hospital discharge, improvement of clinical symptoms (7, 15, and 30 days after transfusion), grade 3 and 4 adverse events, and serious adverse events. MAIN RESULTS: We included eight studies (seven case-series, one prospectively planned, single-arm intervention study) with 32 participants, and identified a further 48 ongoing studies evaluating convalescent plasma (47 studies) or hyperimmune immunoglobulin (one study), of which 22 are randomised. Overall risk of bias of the eight included studies was high, due to: study design; small number of participants; poor reporting within studies; and varied type of participants with different severities of disease, comorbidities, and types of previous or concurrent treatments, including antivirals, antifungals or antibiotics, corticosteroids, hydroxychloroquine and respiratory support. We rated all outcomes as very low certainty, and we were unable to summarise numerical data in any meaningful way. As we identified case-series studies only, we reported results narratively. Effectiveness of convalescent plasma for people with COVID-19 The following reported outcomes could all be related to the underlying natural history of the disease or other concomitant treatment, rather than convalescent plasma. All-cause mortality at hospital discharge All studies reported mortality. All participants were alive at the end of the reporting period, but not all participants had been discharged from hospital by the end of the study (15 participants discharged, 6 still hospitalised, 11 unclear). Follow-up ranged from 3 days to 37 days post-transfusion. We do not know whether convalescent plasma therapy affects mortality (very low-certainty evidence). Improvement of clinical symptoms (assessed by respiratory support) Six studies, including 28 participants, reported the level of respiratory support required; most participants required respiratory support at baseline. All studies reported improvement in clinical symptoms in at least some participants. We do not know whether convalescent plasma improves clinical symptoms (very low-certainty evidence). Time to discharge from hospital Six studies reported time to discharge from hospital for at least some participants, which ranged from four to 35 days after convalescent plasma therapy. Admission on the intensive care unit (ICU) Six studies included patients who were critically ill. At final follow-up the majority of these patients were no longer on the ICU or no longer required mechanical ventilation. Length of stay on the ICU Only one study (1 participant) reported length of stay on the ICU. The individual was discharged from the ICU 11 days after plasma transfusion. Safety of convalescent plasma for people with COVID-19 Grade 3 or 4 adverse events The studies did not report the grade of adverse events after convalescent plasma transfusion. Two studies reported data relating to participants who had experienced adverse events, that were presumably grade 3 or 4. One case study reported a participant who had moderate fever (38.9 °C). Another study (3 participants) reported a case of severe anaphylactic shock. Four studies reported the absence of moderate or severe adverse events (19 participants). We are very uncertain whether or not convalescent plasma therapy affects the risk of moderate to severe adverse events (very low-certainty evidence). Serious adverse events One study (3 participants) reported one serious adverse event. As described above, this individual had severe anaphylactic shock after receiving convalescent plasma. Six studies reported that no serious adverse events occurred. We are very uncertain whether or not convalescent plasma therapy affects the risk of serious adverse events (very low-certainty evidence). AUTHORS' CONCLUSIONS: We identified eight studies (seven case-series and one prospectively planned single-arm intervention study) with a total of 32 participants (range 1 to 10). Most studies assessed the risks of the intervention; reporting two adverse events (potentially grade 3 or 4), one of which was a serious adverse event. We are very uncertain whether convalescent plasma is effective for people admitted to hospital with COVID-19 as studies reported results inconsistently, making it difficult to compare results and to draw conclusions. We identified very low-certainty evidence on the effectiveness and safety of convalescent plasma therapy for people with COVID-19; all studies were at high risk of bias and reporting quality was low. No RCTs or controlled non-randomised studies evaluating benefits and harms of convalescent plasma have been completed. There are 47 ongoing studies evaluating convalescent plasma, of which 22 are RCTs, and one trial evaluating hyperimmune immunoglobulin. We will update this review as a living systematic review, based on monthly searches in the above mentioned databases and registries. These updates are likely to show different results to those reported here.

PubMed Disclaimer

Conflict of interest statement

SJV: none known

VP: none known

KLC: HSANZ Leukaemia Foundation PhD scholarship to support studies at Monash University. This is not related to the work in this review.

CD: none known

IM: none known

EMW: I have sought funding support from Australian Medical Research Future Fund for a trial of convalescent plasma. I will not be involved in bias assessment, data extraction or interpretation, but will serve as a content expert.

AL: none known

CK: none known

ZM: I have sought funding support from Australian Medical Research Future Fund for a trial of convalescent plasma. I will not be involved in bias assessment, data extraction or interpretation, but will serve as a content expert.

CS‐O: is a member of the BEST Collaborative Clinical Study Group. I will not be involved in bias assessment, data extraction or interpretation, but will serve as a content expert.

LJE: co‐lead of the COVID‐19 immunoglobulin domain of the REMAP‐CAP trial. I will not be involved in bias assessment, data extraction or interpretation, but will serve as a content expert.

NS: none known

Figures

1
1
Study flow diagram
2
2
'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study
See this image and copyright information in PMC

Comment in

  • Safety and efficacy of COVID-19 convalescent plasma in severe pulmonary disease: A report of 17 patients.
    Pal P, Ibrahim M, Niu A, Zwezdaryk KJ, Tatje E, Robinson WR 4th, Ko L, Satyavarapu I, Jones WE, Nachabe A, Luk A, Mushatt DM, Halvorson K, Denson JL, Smith CC 3rd, Simeone F, Davis G, Gill SK, McDougal A, Vigh AS, Peterson TG, Ning B, Hu T, Socola F, Robinson J, Safah H, Saba NS. Pal P, et al. Transfus Med. 2021 Jun;31(3):217-220. doi: 10.1111/tme.12729. Epub 2020 Oct 19. Transfus Med. 2021. PMID: 33073895 No abstract available.

References

References to studies included in this review

Ahn 2020 {published data only}
    1. Ahn JY, Sohn Y, Lee SH, Cho Y, Hyun JH, Baek YJ, et al. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. Journal of Korean Medical Science 2020; 35(14):e149. - PMC - PubMed
Duan 2020 {published data only}
    1. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. In: National Academy of Sciences of the United States of America. Vol. 202004168. 2020. [DOI: 10.1073/pnas.2004168117] - DOI - PMC - PubMed
    1. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study. medRxiv 2020. [DOI: ]
Pei 2020 {published data only}
    1. Pei S, Yuan X, Zhimin ZZ, Run YR, Xie Y, Minxue SM, et al. Convalescent plasma to treat COVID-19: Chinese strategy and experiences. medRxiv 2020. [DOI: 10.1101/2020.04.07.20056440] - DOI
Shen 2020 {published data only}
    1. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020. [DOI: 10.1001/jama.2020.4783] - DOI - PMC - PubMed
Tan 2020 {published data only}
    1. Tan L, Kang X, Zhang B, Zheng S, Liu B, Yu T, et al. A special case of COVID-19 with long duration of viral shedding for 49 days. medRxiv 2020. [DOI: 10.1101/2020.03.22.20040071] - DOI - PMC - PubMed
Ye 2020 {published data only}
    1. Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. Journal of Medical Virology 2020. [DOI: 10.1002/jmv.25882] - DOI - PMC - PubMed
Zhang 2020a {published data only}
    1. Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, et al. Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. Chest 2020 Mar 31 [Epub ahead of print]. [DOI: 10.1016/j.chest.2020.03.039] - DOI - PMC - PubMed
Zhang 2020b {published data only}
    1. Zhang L, Pang R, Xue X, Bao J, Ye S, Dai Y, et al. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19. Aging 2020 Apr 22 [Epub ahead of print];12. [DOI: 10.18632/aging.103102] - DOI - PMC - PubMed

References to studies excluded from this review

Bloch 2020 {published data only}
    1. Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. Journal of Clinical Investigation 2020. [DOI: 10.1172/JCI138745] - DOI - PMC - PubMed
Cao 2020 {published data only}
    1. Cao W, Liu X, Bai T, Fan H, Hong K, Song H, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infectious Diseases 2020; 7(3):ofaa102. - PMC - PubMed
Casadevall 2020 {published data only}
    1. Casadevall A, Pirofski L A. The convalescent sera option for containing COVID-19. Journal of Clinical Investigation 2020; 130(4):1545-8. - PMC - PubMed
Chen 2020 {published data only}
    1. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infectious Diseases 2020; 27:27. - PMC - PubMed
ChiCTR2000030312 {published data only}
    1. ChiCTR2000030312. Cancelled, due to modify the protocol A single-center, open-label and single arm trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment& [A single-center, open-label and single arm trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient]. www.chictr.org.cn/showproj.aspx?proj=50258 (first received 23 April 2020).
ChiCTR2000030381 {published data only}
    1. ChiCTR2000030381. Cancelled by investigator A randomized, open-label, controlled and single-center trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient [A randomized, open-label, controlled and single-center trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient]. www.chictr.org.cn/showproj.aspx?proj=50290 (first received 23 April 2020).
ChiCTR2000030442 {published data only}
    1. ChiCTR2000030442. Combination of tocilizumab, IVIG and CRRT in severe patients with novel coronavirus pneumonia (COVID-19). www.chictr.org.cn/showproj.aspx?proj=50380 (first received 23 April 2020).
Díez 2020 {published data only}
    1. Díez JM, Romero C, Gajardo R. Currently available intravenous immunoglobulin (Gamunex-C and Flebogamma© DIF) contains antibodies reacting against SARS-CoV-2 antigens. bioRxiv 2020. [DOI: 10.1101/2020.04.07.029017] - DOI - PMC - PubMed
Hu 2020 {published data only}
    1. Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. European Heart Journal 2020; 16:16. - PMC - PubMed
Jawhara 2020 {published data only}
    1. Jawhara S. Could intravenous immunoglobulin collected from recovered coronavirus patients protect against COVID-19 and strengthen the immune system of new patients? International Journal of Molecular Sciences 2020; 21(7):2272. [DOI: 10.3390/ijms21072272] - DOI - PMC - PubMed
NCT04261426 {published data only}
    1. NCT04261426. The efficacy of intravenous immunoglobulin therapy for severe 2019-nCoV infected pneumonia. clinicaltrials.gov/ct2/show/NCT04261426 (first received 23 April 2020).
NCT04323800 {published data only}
    1. NCT04323800. Convalescent plasma to stem coronavirus: a randomized, blinded phase 2 study comparing the efficacy and safety human coronavirus immune plasma (HCIP) vs. control (SARS-CoV-2 non-immune plasma) among adults exposed to COVID-19. clinicaltrials.gov/show/NCT04323800 (first received 23 April 2020).
NCT04325672 {published data only}
    1. NCT04325672. Convalescent plasma to limit coronavirus associated complications: an open label, phase 2A study of high-titer anti-SARS-CoV-2 plasma in hospitalized patients with COVID-19. clinicaltrials.gov/show/NCT04325672 (first received 23 April 2020).
NCT04344015 {published data only}
    1. NCT04344015. COVID-19 plasma collection. ClinicalTrials.gov/show/NCT04344015 (first received 23 April 2020).
NCT04344977 {published data only}
    1. NCT04344977. COVID-19 plasma collection. clinicaltrials.gov/ct2/show/NCT04344977 (first received 23 April 2020).
Roback 2020 {published data only}
    1. Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA 2020. [DOI: 10.1001/jama.2020.4940] - DOI - PubMed
Shi 2020 {published data only}
    1. Shi H, Zhou C, He P, Huang S, Duan Y, Wang X, et al. Successful treatment of plasma exchange followed by intravenous immunoglobulin in a critically ill patient with 2019 novel coronavirus infection. International Journal of Antimicrobial Agents 2020:105974. - PMC - PubMed
Syal 2020 {published data only}
    1. Syal K. COVID-19: herd immunity and convalescent plasma transfer therapy. Journal of Medical Virology 2020; 13:13. - PMC - PubMed
Tanne 2020 {published data only}
    1. Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. BMJ 2020; 368:m1256. - PubMed
Tiberghien 2020 {published data only}
    1. Tiberghien P, Lambalerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how. Vox Sanguinis 2020. [DOI: 10.1111/vox.12926] - DOI - PubMed
Wong 2020 {published data only}
    1. Wong HK, Lee CK. Pivotal role of convalescent plasma in managing emerging infectious diseases. Vox Sanguinis 2020. [DOI: 10.1111/vox.12927] - DOI - PMC - PubMed
Xie 2020 {published data only}
    1. Xie Y, Cao S, Li Q, Chen E, Dong H, Zhang W, et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. Journal of Infection 2020:S0163-4453(20)30172-9. - PMC - PubMed
Yoo 2020 {published data only}
    1. Yoo JH. Convalescent plasma therapy for corona virus disease 2019: a long way to go but worth trying. Journal of Korean Medical Science 2020; 35(14):e150. - PMC - PubMed
Zhao 2020b {published data only}
    1. Zhao Q, He Y. Challenges of convalescent plasma therapy on COVID-19. Journal of Clinical Virology 2020; 127:104358. - PMC - PubMed

References to studies awaiting assessment

Qiu 2020 {published data only}
    1. Qiu T, Wang J, Zhou J, Zou J, Chen Z, Ma X, et al. The report of two cases infection with novel coronavirus (2019-ncov) after kidney transplantation and the association literature analyzation. Chinese Journal of Organ Transplantation 2020; 41(0):E004.
Tu 2020 {published data only}
    1. Tu Y, Wu X, Liu F, Wang J, Luo Y, Cai Z, et al. Two clinical cases of novel coronavirus pneumonia (NCP) in renal transplant recipients. Chinese Journal of Organ Transplantation 2020; 41(0):E005.

References to ongoing studies

ChiCTR2000029757 {published data only}
    1. ChiCTR2000029757. Convalescent plasma for the treatment of severe and critical novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial. www.chictr.org.cn/showproj.aspx?proj=49081 (first received 12 February 2020).
ChiCTR2000029850 {published data only}
    1. ChiCTR2000029850. Effecacy and safety of convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19): a prospective cohort study. www.chictr.org.cn/showproj.aspx?proj=49533 (first received 15 February 2020).
ChiCTR2000030010 {published data only}
    1. ChiCTR2000030010. A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19). www.chictr.org.cn/showproj.aspx?proj=49777 (first received 19 February 2020).
ChiCTR2000030039 {published data only}
    1. ChiCTR2000030039. Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19). www.chictr.org.cn/showproj.aspx?proj=49544 (first received 21 February 2020).
ChiCTR2000030179 {published data only}
    1. ChiCTR2000030179. Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID-19). www.chictr.org.cn/showproj.aspx?proj=50059 (first received 24 February 2020).
ChiCTR2000030627 {published data only}
    1. ChiCTR2000030627. Study on the application of convalescent plasma therapy in severe COVID-19. www.chictr.org.cn/showproj.aspx?proj=50727 (first received 8 March 2020).
ChiCTR2000030702 {published data only}
    1. ChiCTR2000030702. Convalescent plasma for the treatment of common COVID-19: a prospective randomized controlled trial. www.chictr.org.cn/showproj.aspx?proj=50537 (first received 10 March 2020).
ChiCTR2000030841 {published data only}
    1. ChiCTR2000030841. Treatment of acute severe COVID-19 with immunoglobulin from cured COVID-19 patients. www.chictr.org.cn/showproj.aspx?proj=51072 (first received 15 March 2020).
ChiCTR2000030929 {published data only}
    1. ChiCTR2000030929. A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia (COVID-19). www.chictr.org.cn/showproj.aspx?proj=50696 (first received 17 March 2020).
ChiCTR2000031501 {published data only}
    1. ChiCTR2000031501. The efficacy of convalescent plasma in patients with critical novel coronavirus pneumonia (COVID-19): a pragmatic, prospective cohort study. www.chictr.org.cn/showproj.aspx?proj=50254 (first received 2 April 2020).
EUCTR2020‐001310‐38 {published data only}
    1. EUCTR2020-001310-38. A randomized, prospective, open label clinical trial on the use of convalescent plasma compared to best supportive care in patients with severe COVID-19. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:202... (first received 23 April 2020).
IRCT20151228025732N53 {published data only}
    1. IRCT20151228025732N53. Therapeutic effects of plasma of recovered people from COVID-19 on hospitalized patients with this disease. en.irct.ir/trial/46931 (first received 10 April 2020).
IRCT20200310046736N1 {published data only}
    1. IRCT20200310046736N1. Comparison of the therapeutic effect of convalescent plasma and plasma-derived immunoglobulin-enriched solution on COVID-19 patients. en.irct.ir/trial/46424 (first received 1 April 2020).
IRCT20200325046860N1 {published data only}
    1. IRCT20200325046860N1. Convalescent plasma therapy for COVID-19 patients. en.irct.ir/trial/46759 (first received 30 March 2020).
IRCT20200404046948N1 {published data only}
    1. IRCT20200404046948N1. Efficacy and safety of convalescent plasma in the treatment of COVID-19. en.irct.ir/trial/46973 (first received 15 April 2020).
IRCT20200409047007N1 {published data only}
    1. IRCT20200409047007N1. Effect of COVID 19 survivors plasma in COVID 19 patients with ARDS. en.irct.ir/trial/47058 (first received 12 April 2020).
IRCT20200413047056N1 {published data only}
    1. IRCT20200413047056N1. Comparison between the efficacy of intravenous immunoglobulin and convalescent plasma in COVID-19. en.irct.ir/trial/47212 (first received 17 April 2020).
NCT04264858 {published data only}
    1. NCT04264858. An exploratory clinical study on the treatment of acute severe 2019-nCoV pneumonia with immunoglobulin from cured 2019-nCoV pneumonia patients. clinicaltrials.gov/show/NCT04264858 (first received 11 February 2020).
NCT04292340 {published data only}
    1. NCT04292340. The efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19): an observational study. clinicaltrials.gov/show/NCT04292340 (first received 3 March 2020).
NCT04321421 {published data only}
    1. NCT04321421. Plasma from donors recovered from new coronavirus 2019 as therapy for critical patients with COVID-19. clinicaltrials.gov/show/NCT04321421 (first received 25 March 2020).
NCT04327349 {published data only}
    1. NCT04327349. Investigating effect of convalescent plasma on COVID-19 patients outcome: a clinical trial. clinicaltrials.gov/show/NCT04327349 (first received 31 March 2020).
NCT04332380 {published data only}
    1. NCT04332380. Convalescent plasma for patients with COVID-19: a pilot study. clinicaltrials.gov/show/NCT04332380 (first received 2 April 2020).
NCT04332835 {published data only}
    1. NCT04332835. Convalescent plasma for patients with COVID-19: a randomized, open label, parallel, controlled clinical study. clinicaltrials.gov/show/NCT04332835 (first received 3 April 2020).
NCT04333251 {published data only}
    1. NCT04333251. Evaluating convalescent plasma to decrease coronavirus associated complications. A phase I study comparing the efficacy and safety of high-titer anti-Sars-CoV-2 plasma vs best supportive care in hospitalized patients with interstitial pneumonia due to COVID-19. clinicaltrials.gov/show/NCT04333251 (first received 3 April 2020).
NCT04333355 {published data only}
    1. NCT04333355. Phase 1 study to evaluate the safety of convalescent plasma as an adjuvant therapy in patients with SARS-CoV-2 infection. clinicaltrials.gov/show/NCT04333355 (first received 3 April 2020).
NCT04338360 {published data only}
    1. NCT04338360. Expanded access to convalescent plasma for the treatment of patients with COVID-19. ClinicalTrials.gov/show/NCT04338360 (first received 8 April 2020).
NCT04340050 {published data only}
    1. NCT04340050. COVID-19 convalescent plasma. ClinicalTrials.gov/show/NCT04340050 (first received 9 April 2020).
NCT04342182 {published data only}
    1. NCT04342182. Convalescent plasma as therapy for Covid-19 severe SARS-CoV-2 disease (CONCOVID Study) (ConCoVid-19). ClinicalTrials.gov/show/NCT04342182 (first received 10 April 2020).
NCT04343261 {published data only}
    1. NCT04343261. Convalescent plasma in the treatment of COVID 19. ClinicalTrials.gov/show/NCT04343261 (first received 13 April 2020).
NCT04343755 {published data only}
    1. NCT04343755. Convalescent plasma as treatment for hospitalized subjects with COVID-19 infection. ClinicalTrials.gov/show/NCT04343755 (first received 13 April 2020).
NCT04344535 {published data only}
    1. NCT04344535. Convalescent plasma vs. standard plasma for COVID-19. ClinicalTrials.gov/show/NCT04344535 (first received 14 April 2020).
NCT04345289 {published data only}
    1. EUCTR2020-001367-88-DK. Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2020-001367-88-DK (first received 14 April 2020).
    1. NCT04345289. Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia (CCAP). ClinicalTrials.gov/show/NCT04345289 (first received 14 April 2020).
NCT04345523 {published data only}
    1. NCT04345523. Convalescent plasma therapy vs. SOC for the treatment of COVID19 in hospitalized patients (ConPlas-19). ClinicalTrials.gov/show/NCT04345523 (first received 14 April 2020).
NCT04345679 {published data only}
    1. NCT04345679. Anti COVID-19 convalescent plasma therapy. ClinicalTrials.gov/show/NCT04345679 (first received 14 April 2020).
NCT04345991 {published data only}
    1. NCT04345991. Efficacy of convalescent plasma to treat COVID-19 patients, a nested trial in the CORIMUNO-19 cohort. ClinicalTrials.gov/show/NCT04345991 (first received 15 April 2020).
NCT04346446 {published data only}
    1. NCT04346446. Efficacy of convalescent plasma therapy in severely sick COVID-19 patients. ClinicalTrials.gov/show/NCT04346446 (first received 15 April 2020).
NCT04346589 {published data only}
    1. NCT04346589. Convalescent antibodies infusion in critically ill COVID 19 patients. clinicaltrials.gov/ct2/show/NCT04346589 (first received 15 April 2020).
NCT04347681 {published data only}
    1. NCT04347681. Potential efficacy of convalescent plasma to treat severe COVID-19 and patients at high risk of developing severe COVID-19. ClinicalTrials.gov/show/NCT04347681 (first received 15 April 2020).
NCT04348656 {published data only}
    1. NCT04348656. Convalescent plasma for hospitalized adults with COVID-19 respiratory illness (CONCOR-1). ClinicalTrials.gov/show/NCT04348656 (first received 16 April 2020).
NCT04348877 {published data only}
    1. NCT04348877. Plasma rich antibodies from recovered patients from COVID19. ClinicalTrials.gov/show/NCT04348877 (first received 16 April 2020).
NCT04352751 {published data only}
    1. NCT04352751. Experimental use of convalescent plasma for passive immunization in current COVID-19 pandemic in Pakistan in 2020. ClinicalTrials.gov/show/NCT04352751 (first received 20 April 2020).
NCT04353206 {published data only}
    1. NCT04353206. Convalescent plasma in ICU patients with COVID-19-induced respiratory failure. ClinicalTrials.gov/show/NCT04353206 (first received 20 April 2020).
NCT04354831 {published data only}
    1. NCT04354831. A study evaluating the efficacy and safety of high-titer anti-SARS-CoV-2 plasma in hospitalized patients with COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04354831 (first received 21 April 2020).
NCT04355767 {published data only}
    1. NCT04355767. Convalescent plasma vs. placebo in emergency room patients with COVID-19. clinicaltrials.gov/ct2/show/NCT04355767 (first received 21 April 2020).
NCT04355897 {published data only}
    1. NCT04355897. CoVID-19 plasma in treatment of COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04355897 (first received 21 April 2020).
NCT04356482 {published data only}
    1. NCT04356482. Convalescent plasma for ill patients by COVID-19. ClinicalTrials.gov/show/NCT04356482 (first received 22 April 2020).
NCT04356534 {published data only}
    1. NCT04356534. Convalescent plasma trial in COVID -19 patients. ClinicalTrials.gov/show/NCT04356534 (first received 22 April 2020).
NCT04357106 {published data only}
    1. NCT04357106. COPLA study: treatment of severe forms of coronavirus infection with convalescent plasma. ClinicalTrials.gov/show/NCT04357106 (first received 22 April 2020).

Additional references

Bao 2020
    1. Bao L, Deng W, Gao H, Xiao C, Liu J, Xue J, et al. Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. bioRxiv (accessed 13 April 2020). [DOI: 10.1101/2020.03.13.990226] - DOI
Baudel 2020
    1. Baudel JL, Vigneron C, Pras-Landre V, Joffre J, Marjot F, Ait-Oufella H, et al. Transfusion-related acute lung injury (TRALI) after intravenous immunoglobulins: French multicentre study and literature review. Clinical Rheumatology 2020; 39(2):541-6. - PubMed
Beigel 2017
    1. Beigel JH, Tebas P, Elie-Turenne MC, Bajwa E, Bell TE, Cairns B, et al. Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. Lancet Respiratory Medicine 2017; 5(6):500-11. [DOI: 10.1016/S2213-2600(17)30174-1] - DOI - PMC - PubMed
Beigel 2019
    1. Beigel JH, Aga E, Elie-Turenne M-C, Cho J, Tebas P, Clark CL, et al. Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. Lancet Respiratory Medicine 2019; 7(11):941-50. [DOI: 10.1016/S2213-2600(19)30199-7] - DOI - PMC - PubMed
Brennan 2003
    1. Brennan VM, Salomé-Bentley NJ, Chapel HM, Immunology Nurses Study. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clinical and Experimental Immunology 2003; 133(2):247-51. - PMC - PubMed
CDC 2020a
    1. Centers for Disease Control and Prevention (CDC). Coronavirus Disease 2019 (COVID-19). www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html (accessed 13 April 2020).
CDC 2020b
    1. Centers for Disease Control and Prevention (CDC). Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19). www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patie... (last accessed 26 April 2020).
Chun 2016
    1. Chun S, Chung CR, Ha YE, Han TH, Ki CS, Kang ES, et al. Possible transfusion-related acute lung injury following convalescent plasma transfusion in a patient with Middle East respiratory syndrome. Annals of Laboratory Medicine 2016; 36(4):393-5. [DOI: 10.3343/alm.2016.36.4.393] - DOI - PMC - PubMed
COMET 2020
    1. Core outcome set developers’ response to COVID-19 (2nd April 2020). www.comet-initiative.org/Studies/Details/1538 (accessed 9 April 2020).
Covidence [Computer program]
    1. Veritas Health Innovation Covidence. Version accessed 20 April 2020. Melbourne, Australia: Veritas Health Innovation.Available at covidence.org.
Davey 2019
    1. Davey RT Jr, Fernández-Cruz E, Markowitz N, Pett S, Babiker AG, Wentworth D, et al. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. Lancet Respiratory Medicine 2019; 7(11):951-63. [DOI: 10.1016/S2213-2600(19)30253-X] - DOI - PMC - PubMed
Deeks 2019
    1. Deeks JJ, Higgins JP, Altman DG, editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.
Driggin 2020
    1. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. Journal of the American College of Cardiology 2020; 75(18):2352-71. - PMC - PubMed
Eibl 2008
    1. Eibl MM. History of immunoglobulin replacement. Immunology and Allergy Clinics of North America 2008; 28(4):737-64. [DOI: 10.1016/j.iac.2008.06.004] - DOI - PubMed
EPOC 2017
    1. Cochrane Effective Practice and Organisation of Care (EPOC). What study designs can be considered for inclusion in an EPOC review and what should they be called? EPOC Resources for review authors. Available from epoc.cochrane.org/resources/epoc-resources-review-authors (accessed 23 April 2019).
GRADEpro GDT [Computer program]
    1. McMaster University (developed by Evidence Prime) GRADEpro GDT. Version accessed 20 April 2020. Hamilton (ON): McMaster University (developed by Evidence Prime).Available at gradepro.org.
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-60. - PMC - PubMed
Higgins 2019a
    1. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook. - PMC - PubMed
Higgins 2019b
    1. Higgins JP, Deeks JJ, editor(s). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.
Ho 2005
    1. Ho MS, Chen WJ, Chen HY, Lin SF, Wang MC, Di J, et al. Neutralizing antibody response and SARS severity. Emerging Infectious Diseases 2005; 11(11):1730-7. - PMC - PubMed
Huang 2020
    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223):497-506. [DOI: 10.1016/S0140-6736(20)30183-5] - DOI - PMC - PubMed
Hung 2013
    1. Hung IF, To KK, Lee CK, Lee KL, Yan WW, Chan K, et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 2013; 144(2):464-73. [DOI: 10.1378/chest.12-2907] - DOI - PubMed
Kim 2020
    1. Kim D-H, Choe YJ, Jeong J-Y. Understanding and interpretation of case fatality rate of coronavirus disease 2019. Journal of Korean Medical Science 2020; 35(12):e137. [DOI: 10.3346/jkms.2020.35.e137] - DOI - PMC - PubMed
Kreijtz 2011
    1. Kreijtz JH, Fouchier RA, Rimmelzwaan GF. Immune responses to influenza virus infection. Virus Research 2011; 162(1-2):19-30. [DOI: 10.1016/j.virusres.2011.09.022] - DOI - PubMed
Lauer 2020
    1. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Annals of Internal Medicine 2020. [DOI: 10.7326/M20-0504] - DOI - PMC - PubMed
Lefebvre 2019
    1. Lefebvre C, Glanville J, Briscoe S, Littlewood A, Marshall C, Metzendorf MI, et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.
Li 2019
    1. Li T, Higgins JP, Deeks JJ, editor(s). Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.
Liang 2020
    1. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncology 2020; 21(3):335-7. [DOI: 10.1016/S1470-2045(20)30096-6] - DOI - PMC - PubMed
Luke 2006
    1. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Annals of Internal Medicine 2006; 145(8):599-609. - PubMed
Mair‐Jenkins 2015
    1. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. Journal of Infectious Diseases 2015; 211(1):80-90. [DOI: 10.1093/infdis/jiu396] - DOI - PMC - PubMed
Microsoft Corporation 2018 [Computer program]
    1. Microsoft Corporation, available at: office.microsoft.com/excel Mircosoft Excel. Microsoft Corporation. Microsoft Corporation, available at: office.microsoft.com/excel, 2018.
Mo 2006
    1. Mo H, Zeng G, Ren X, Li H, Ke C, Tan Y, et al. Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance. Respirology 2006; 11(1):49-53. [DOI: 10.1111/j.1440-1843.2006.00783.x] - DOI - PMC - PubMed
Moher 2009
    1. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology 2009; 62(10):1006-12. - PubMed
Morens 1994
    1. Morens DM. Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clinical Infectious Diseases 1994; 19(3):500-12. - PubMed
Mulder 2019
    1. Mulder RL, Bresters D, Van den Hof M, Koot BG, Castellino SM, Loke YK, et al. Hepatic late adverse effects after antineoplastic treatment for childhood cancer. Cochrane Database of Systematic Reviews 2019, Issue 4. [DOI: 10.1002/14651858.CD008205.pub3] - DOI - PMC - PubMed
Otrock 2017
    1. Otrock ZK, Liu C, Grossman BJ. Transfusion‐related acute lung injury risk mitigation: an update. Vox Sanguinis 2017; 112(8):694-703. - PubMed
Pandey 2012
    1. Pandey S, Vyas GN. Adverse effects of plasma transfusion. Transfusion 2012; 52 Suppl 1:65S-79S. - PMC - PubMed
Parmar 1998
    1. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998; 17(24):2815-34. - PubMed
Payne 2016
    1. Payne DC, Iblan I, Rha B, Algasrawi S, Hin A, Al Nsour M, et al. Persistence of antibodies against Middle East respiratory syndrome coronavirus. Emerging Infectious Disease Journal 2016; 22(10):1824-6. [DOI: 10.3201/eid2210.160706] - DOI - PMC - PubMed
Reeves 2019
    1. Reeves BC, Deeks JJ, Higgins JP, Shea B, Tugwell P, Wells GA. Chapter 24: Including non-randomized studies on intervention effects. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.
Review Manager Web [Computer program]
    1. The Cochrane Collaboration Review Manager Web (RevMan Web). The Cochrane Collaboration, 2019.Available from revman.cochrane.org.
Ricke 2020
    1. Ricke D, Malone R. Medical countermeasures analysis of 2019-nCoV and vaccine risks for antibody-dependent enhancement (ADE). www.preprints.org/manuscript/202003.0138/v1 2020; 2020030138. [DOI: 10.20944/preprints202003.0138.v1] - DOI
Robbins 1995
    1. Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. Journal of Infectious Diseases 1995; 171(6):1387-98. - PubMed
Rock 2011
    1. Rock G. A comparison of methods of pathogen inactivation of FFP. Vox Sanguinis 2011; 100(2):169-78. - PubMed
Schünemann 2019
    1. Schünemann HJ, Vist GE, Higgins JP, Santesso N, Deeks JJ, Glasziou P, et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.
Sekul 1994
    1. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Annals of Internal Medicine 1994; 121(4):259-62. - PubMed
Sterne 2016
    1. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016; 355:i4919. - PMC - PubMed
Sterne 2019
    1. Sterne JA, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366:l4898. - PubMed
Stiehm 2013
    1. Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfusion Medicine Reviews 2013; 27(3):171-8. - PubMed
Team 2020
    1. Team NCPERE . Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) – China. China CDC Weekly 2020; 2(8):113-22. [DOI: 10.3760/cma.j.issn.0254-6450.2020.02.003] - DOI - PMC - PubMed
Tierney 2007
    1. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8:16. - PMC - PubMed
Tolouian 2020
    1. Tolouian R, Vahed SZ, Ghiyasvand S, Tolouian A, Ardalan M. COVID-19 interactions with angiotensin-converting enzyme 2 (ACE2) and the kinin system; looking at a potential treatment. Journal of Renal Injury Prevention 2020; 9(2):e19. [DOI: 10.34172/jrip.2020.19] - DOI
Van de Veerdonk 2020
    1. Van de Veerdonk F, Netea MG, Van Deuren M, Van der Meer JW, De Mast Q, Bruggemann RJ, et al. Kinins and cytokines in COVID-19: a comprehensive pathophysiological approach. Preprints 2020 (accessed 13 April 2020);2020040023. [DOI: 10.20944/preprints202004.0023.v1] - DOI
Wan 2020
    1. Wan Y, Shang J, Sun S, Tai W, Chen J, Geng Q, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. Journal of Virology 2020; 94(5):e02015-19. - PMC - PubMed
Wang 2014
    1. Wang S-F, Tseng S-P, Yen C-H, Yang J-Y, Tsao C-H, Shen C-W, et al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochemical and Biophysical Research Communications 2014; 451(2):208-14. - PMC - PubMed
WHO 2007
    1. World Health Organization (WHO). Cumulative number of reported probable cases of SARS. www.who.int/csr/sars/country/2003_07_11/en/ (accessed 13 April 2020).
WHO 2019
    1. World Health Organization (WHO). Middle East respiratory syndrome coronavirus (MERS-CoV). www.who.int/emergencies/mers-cov/en/ (accessed 13 April 2020).
WHO 2020a
    1. World Health Organization (WHO). Report of the WHO‐China Joint Mission on coronavirus disease 2019 (COVID‐19); February 2020. Available at www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-....
WHO 2020b
    1. World Health Organization (WHO). Rolling updates on coronavirus diseases (COVID‐19). www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-h... (accessed 13 April 2020).
WHO 2020c
    1. World Health Organization (WHO). Coronavirus disease (COVID-2019) situation report-105; 4 May 2020. Available at www.who.int/docs/default-source/coronaviruse/situation-reports/20200504-....
WHO 2020d
    1. World Health Organization (WHO). Clinical management of severe acute respiratory infection (SARI) when COVID19 disease is suspected: interim guidance. World Health Organization 2020; WHO/2019-nCoV/clinical/2020.4.
Wu 2020a
    1. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Internal Medicine 2020. [DOI: 10.1001/jamainternmed.2020.0994] - DOI - PMC - PubMed
Wu 2020b
    1. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv (accessed 13 April 2020). [DOI: ]
Xu 2020
    1. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respiratory Medicine 2020; 8(4):420-2. [DOI: 10.1016/S2213-2600(20)30076-X] - DOI - PMC - PubMed
Zhao 2020
    1. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. medRxiv 2020. [DOI: 10.1101/2020.03.02.20030189] - DOI - PMC - PubMed

References to other published versions of this review

Piechotta 2020
    1. Piechotta V, Valk SJ, Chai KL, Wood EM, Lamikanra A, Kimber C, et al. Safety and effectiveness of convalescent plasma or hyperimmune globulin for people with COVID-19: a rapid review. available at: doi.org/10.17605/OSF.IO/DWF53.

Publication types

Substances